Actuarial disease-free survival after prostate cancer brachytherapy using interactive techniques with biplane ultrasound and fluoroscopic guidance

International Journal of Radiation Oncology Biology Physics

Volumn 42, Issue 2, 1998, Pages 289-298

  Grado, Gordon L ^a,d,e   Larson, Thayne R ^a   Balch, Carrie S ^a,d   Grado, Mary M ^e   Collins, Joseph M ^a   Kriegshauser, J Scott ^a   Swanson, Gregory P ^c   Navickis, Roberta J ^b   Wilkes, Mahlon M ^b  

^a MAYO CLINIC   (United States)

^b Hygeia Associates   (United States)

^c SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^d Carle Clinic   (United States)

^e NONE

Author keywords

Brachytherapy; Iodine; Palladium; Prostate carcinoma; Prostate specific antigen

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ANTIANDROGEN; GONADORELIN AGONIST; IODINE 125; PALLADIUM; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; AGED; ARTICLE; BEAM THERAPY; BRACHYTHERAPY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; ENZYME IMMUNOASSAY; FLUOROSCOPY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; SAFETY;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BRACHYTHERAPY; DISEASE-FREE SURVIVAL; FLUOROSCOPY; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TREATMENT FAILURE;

EID: 0032171036     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(98)00209-0     Document Type: Article

References (44)

1. Weyrich T.P., Kandzari S.J., Jain P.R. Iodine 125 seed implants for prostatic carcinoma. Five- and ten-year follow-up. Urology. 41:1993;122-126.
2. Adolfsson J., Brehmer M., Naslund E., Johansson L., Ekman P., Andersson L. Iodine-125 brachytherapy for clincally localized prostate cancer A 5-year follow-up of outcome and complications . Eur Urol. 26:1994;207-211.
3. 125iodine implantation to control localized prostate cancer A study of 41 patients . J Urol. 146:1991;1317-1319.
4. 125iodine implantation of the prostrate for clinically localized prostate cancer A study of 41 patients . J Urol. 158:1997;23-30.
5. 103Pd brachytherapy and external beam irradiation for clinically localized, high-risk prostatic carcinoma. Int J Radiat Oncol Biol Phys. 35:1996;875-879.
6. D'Amico A.V., Coleman C.N. Role of interstitial radiotherapy in the management of clinically organ-confined prostate cancer The jury is still out . J Clin Oncol. 14:1996;304-315.
7. 125I prostate implantation. Int J Radiat Oncol Biol Phys. 37:1997;559-563.
8. 125iodine implantation for stage T1/T2 prostatic carcinoma. J Urol. 154:1995;1096-1099.
9. Blasko J.G., Grimm P.D., Padge H. External beam irradiation with palladium-103 implantation for prostate carcinoma. Int J Radiat Oncol Biol Phys. 30:(Suppl. 1):1994;219.
10. Critz F.A., Tarlton R.S., Holladay D.A. Prostate specific antigen-monitored combination radiotherapy for patients with prostate cancer. I-125 implant followed by external-beam radiation. Cancer. 75:1995;2383-2391.
11. Kaye K.W., Olson D.J., Payne J.T. Percutaneous iodine-125 seed implantation for carcinoma of the prostate. Aust N Z J Surg. 65:1995;658-663.
12. 125iodine implantation for localized prostate cancer using percutaneous approach. J Urol. 153:1995;1020-1025.
13. Radge H., Blasko J.C., Grimm P.D., Kenny G.M., Sylvester J.E., Hoak D.C., Landin K., Cavanagh W. Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma. Cancer. 80:1997;442-453.
14. Stock R.G., Stone N.N., DeWyngaert J.K., Lavagnini P., Unger P.D. Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma. Cancer. 77:1996;2386-2392.
15. Stokes S.H., Real J.D., Adams P.W., Clements J.C., Wuertzer S., Kan W. Transperineal ultrasound-guided radioactive seed implantation for organ-confined carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 37:1997;337-341.
16. Wallner K., Roy J., Zelefsky M., Fuks Z., Harrison L. Short-term freedom from disease progression after I-125 prostate implantation. Int J Radiat Oncol Biol Phys. 30:1994;405-409.
17. Wallner K., Roy J., Harrison L. Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma. J Clin Oncol. 14:1995;449-453.
18. Utz D.C., Farrow G.M. Pathologic differentiation and prognosis of prostatic carcinoma. JAMA. 209:1969;1701-1703.
19. Gleason D.F. Histologic grading and clinical staging of prostatic carcinoma. Tannenbaum M. Urologic pathology The prostate . 1997;171-198 Lee & Febinger, Philadelphia.
20. 125iodine seed implantation in prostatic cancer guided by transrectal ultrasonography. J Urol. 130:1983;283-286.
21. Nag S. Transperineal iodine-125 implantation of the prostate under transrectal ultrasound and fluoroscopic control. Endocurie/Hypertherm Oncol. 1:1985;207-211.
22. Radge H., Blasko J.C., Schumacher D. Use of transrectal ultrasound in transperineal iodine-125 seeding for prostate cancer Methodology . J Endourol. 3:1989;209-218.
23. Nath R., Anderson L.L., Luxton G., Weaver K.A., Williamson J.F., Meigooni A.S. Dosimetry of interstitial brachytherapy sources Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43 . Med Phys. 22:1995;209-234.
24. 125I transperineal prostate seed implants on commercial treatment planning systems. Int J Radiat Oncol Biol Phys. 37:1997;737-741.
25. Kaplan I.D., Cos R.S., Bagshaw M.A. Prostate specific antigen after external beam radiotherapy for prostatic cancer Followup . J Urol. 149:1993;519-522.
26. Arterbery V.E., Wallner K., Roy J., Fuks Z. Short-term morbidity from CT-planned transperineal I-125 prostate implants. Int J Radiat Oncol Biol Phys. 25:1993;661-667.
27. Blasko J.C., Ragde H., Grimm P.D. Transperineal ultrasound-guided implantation of the prostate Morbidity and complications . Scand J Urol Nephrol Suppl. 137:1991;113-118.
28. Vijverberg P.L., Kurth K.H., Blank L.E., Dabhoiwala N.F., de Reijke T.H., Koedooder K. Treatment of localized prostatic carcinoma using the transrectal ultrasound guided transperineal implantation technique. Eur Urol. 21:1992;35-41.
29. Althof V.G., Hoekstra C.J., te Loo H.J. Variation in prostate position relative to adjacent bony anatomy. Int J Radiat Oncol Biol Phys. 34:1996;709-715.
30. Blasko J.C., Grimm P.D., Ragde H. Brachytherapy and organ preservation in the management of carcinoma of the prostate. Semin Radiat Oncol. 3:1993;240-249.
31. Wallner K., Lee H., Wasserman S., Dattoli M. Low risk of urinary incontinence following prostate brachytherapy in patients with a prior transurethral prostate resection. Int J Radiat Oncol Biol Phys. 37:1997;565-569.
32. Holtgrewe H.L., Mebust W.K., Dowd J.B., Cockett A.T.K., Peters P.C., Proctor C. Transurethral prostatectomy Practice aspects of the dominant operation in American urology . J Urol. 141:1989;248-253.
33. Pollack A., Zagars G.K., Kavadi V.S. Prostate-specific antigen doubling time and disease relapse after radiotherapy for prostate cancer. Cancer. 74:1994;670-680.
34. Chauvet B., Felix-Faure C., Lupsascka N., Fijuth J., Brewer Y., Davin J.L., Kirscher S., Reboul F. Prostate-specific antigen decline A major prognostic factor for prostate cancer treated with radiation therapy . J Clin Oncol. 12:1994;1402-1407.
35. Critz F.A., Levinson A.K., Williams W.H., Holladay D.A., Holladay C.T. The PSA nadir that indicates potential cure after radiotherapy for prostate cancer. Urology. 49:1997;322-326.
36. Hanks G.E. Treatment of early stage prostate cancer Radiotherapy . DeVita V.T., Hellman S., Rosenberg S.A. Important advances in oncology. 1994;225-239 Lippincott, Philadelphia.
37. Lee W.R., Hanlon A.L., Hanks G.E. Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer. The relationship between nadir level and disease-free survival. J Urol. 156:1996;450-453.
38. Pisansky T.M., Cha S.S., Earle J.D., Durr E.D., Kozelsky T.F., Wieand H.S., Oesterling J.E. Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer. J Clin Oncol. 11:1993;2158-2166.
39. Zietmen A.L., Coen J.J., Shipley W.U., Willett G.C., Efird J.T. Radical radiation therapy in the management of prostatic adenocarcinoma The initial prostate specific antigen value as a predictor of treatment outcome . J Urol. 151:1994;640-645.
40. Schellhammer P.F., el-Mahdi A.M., Wright G.L., Kolm P., Ragle R. Prostate-specific antigen to determine progression-free survival after radiation therapy for localized carcinoma of prostate. Urology. 42:1993;13-20.
41. Rosenzweig K.E., Morgan W.R., Lytton B., Peschel R.E. Prostate specific antigen following radiotherapy for local prostate cancer. J Urol. 153:1995;1561-1564.
42. Anderson L.L., Moni J.V., Harrison L.B. A nomograph for permanent implants of palladium-103 seeds. Int J Radiat Oncol Biol Phys. 27:1993;129-135.
43. Stone N.N., Stock R.G. Brachytherapy for prostate cancer Real-time three-dimensional interactive seed implantation . Tech Urol. 1:1995;72-80.
44. Swanson G.P., Cupps R.E., Utz D.C., Ilstrup D.M., Zincke H., Myers R.P. Definitive therapy for prostate carcinoma Mayo Clinic results at 15 years after treatment . Br J Radiol. 67:1994;877-889.